# Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

> **NCT00577629** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 39 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** rituximab
- **DRUG:** cytarabine
- **DRUG:** doxorubicin
- **DRUG:** tositumomab

## Key facts

- **NCT ID:** NCT00577629
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-18
- **Primary completion:** 2012-04-08
- **Final completion:** 2016-11-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577629, "Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00577629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*